Rate of pathology from atypical glandular cell Pap tests classified by the Bethesda 2001 nomenclature.
about
Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancersManagement of borderline change in endocervical cells: a more dependable approachAtypical endometrial cells and atypical glandular cells favor endometrial origin in Papanicolaou cervicovaginal tests: Correlation with histologic follow-up and abnormal clinical presentations.Cervical intraepithelial lesions in females attending Women's Health Clinics in Alexandria, EgyptThe Value of Papanicolaou Tests in the Diagnosis of Endometrial Carcinoma: A Large Study Cohort From an Academic Medical Center.Cervicovaginal cytology and diagnosis of ovarian or peritoneal cancer: case report and literature review.Pooled analysis of the performance of liquid-based cytology in population-based cervical cancer screening studies in ChinaClinical significance of atypical glandular cells in the Bethesda system 2001: a comparison with the histopathological diagnosis of surgically resected specimens.High-risk HPV testing in the management of atypical glandular cells: A systematic review and meta-analysis.Assessment of reflex human papillomavirus DNA testing in patients with atypical endocervical cells on cervical cytology.Histological Follow-Up in Patients with Atypical Glandular Cells on Pap Smears.Clinical significance of atypical glandular cells on Pap smears: experience from a region with a high incidence of cervical cancer.Adherence to practice guidelines for atypical glandular cells on cervical cytology.Factors predicting pathologic significance among women with atypical glandular cells on liquid-based cytology.Diagnostic and therapeutic dilemma associated with atypical glandular cells on liquid-based cervical cytology.Clinicopathological significance of atypical glandular cells on cervicovaginal Pap smears.
P2860
Q28282973-21AEC8B5-16A5-4380-B74D-39A2C2933F3AQ34113493-1DFDA9E0-82FD-44CB-A60C-268451C45FBEQ34617400-DA6352CC-CA59-4040-BF67-F8038A078E32Q35796499-39F57466-16FB-4529-A9C1-E71B3B639012Q36002181-DFC8AEDF-C913-4F8A-854A-08C88176FC0AQ36892207-0E699E55-3DF3-474F-802F-458399B5954CQ37179540-E4951702-E533-4420-A240-60EEA65DCB23Q37728563-66A41C53-66E5-4301-B3B9-3D8B05975617Q38316273-10517408-1A4E-4287-B4CB-5ABA543D2992Q43818183-79BCF6EB-2691-4C2B-BA07-80F17E730668Q44447286-81DB4294-2BAC-4E90-A9EA-2D0FF04C1073Q44928069-EB0550A8-A95F-466F-8930-96E9A65A215CQ45823682-C9252424-1D40-48F7-B2E9-8AF9CD3BC024Q47352406-61E12DBE-B978-4785-BCA4-38409B628D0AQ47769629-AC18BCC7-5B30-4BA6-A391-BAA507D22BBEQ48296316-87678EA9-7589-428A-9B42-F1109D86C26A
P2860
Rate of pathology from atypical glandular cell Pap tests classified by the Bethesda 2001 nomenclature.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Rate of pathology from atypica ...... he Bethesda 2001 nomenclature.
@ast
Rate of pathology from atypica ...... he Bethesda 2001 nomenclature.
@en
type
label
Rate of pathology from atypica ...... he Bethesda 2001 nomenclature.
@ast
Rate of pathology from atypica ...... he Bethesda 2001 nomenclature.
@en
prefLabel
Rate of pathology from atypica ...... he Bethesda 2001 nomenclature.
@ast
Rate of pathology from atypica ...... he Bethesda 2001 nomenclature.
@en
P2093
P1476
Rate of pathology from atypica ...... he Bethesda 2001 nomenclature.
@en
P2093
Charles S Dietrich
Christopher P DeSimone
Mary L Eastham
Misty E Day
Molly M Tovar
Susan C Modesitt
P304
P356
10.1097/01.AOG.0000218705.87329.4A
P407
P577
2006-06-01T00:00:00Z